Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE)
1Guangdong Province Key Laboratory of Functional Molecules in Oceanic Microorganism, Zhong Shan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, People’s Republic of China.
BMC Structural Biology
|August 29, 2012
Summary
Quantitative structure-activity relationship (QSAR) models were developed using comparative binding energy analysis of beta-secretase 1 (BACE-1) inhibitor complexes. These models offer insights for designing novel Alzheimer disease therapeutics by optimizing ligand-protein interactions.
Area of Science:
- Biochemistry
- Drug Discovery
- Computational Chemistry
Background:
- Beta-secretase (BACE-1) inhibition is a key strategy for Alzheimer disease treatment.
- Understanding BACE-1 inhibitor mechanisms is crucial for therapeutic development.
- X-ray crystallography provides detailed structural information on enzyme-inhibitor interactions.
Purpose of the Study:
- To develop quantitative structure-activity relationship (QSAR) models for BACE-1 inhibitors.
- To elucidate the binding mechanisms of BACE-1 inhibitors using computational approaches.
- To identify key protein residues and interactions involved in BACE-1 inhibition.
Main Methods:
- Utilized 46 X-ray crystallographic BACE-1/inhibitor complexes.
- Aligned inhibitors by superimposing crystal structures.
- Performed Comparative Binding Energy (COMBINE) analysis using gCOMBINE software.
- Derived QSAR models based on protein residue contributions to interaction energies.
Main Results:
- Developed two predictive and robust COMBINE models: a 3-PC distance-dependent dielectric model (q2=0.74, SDEC=0.521) and a 5-PC sigmoidal electrostatic model (q2=0.79, SDEC=0.41).
- Models quantitatively identified key residues and interaction types critical for BACE-1 inhibition.
- Electrostatic and van der Waals interactions were significant contributors to binding.
Conclusions:
- The developed QSAR models provide valuable insights into BACE-1 inhibition.
- These models can guide the rational design of novel BACE-1 inhibitors.
- Optimization of ligand interactions with key BACE-1 residues is essential for drug development.
Related Concept Videos
02:18The Equilibrium Binding Constant and Binding Strength
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
02:18The Equilibrium Binding Constant and Binding Strength
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
01:49Conserved Binding Sites
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
01:49Conserved Binding Sites
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
01:16Protein-Drug Binding: Mechanism and Kinetics
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
01:22Protein-Drug Binding: Determination Methods
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...